UTv Videos

Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer.

Stacy Loeb, MD, shares key takeaways from her LUGPA 2025 session, “Current state of prostate cancer screening.”

Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.

Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing

Andrew W. Hahn, MD, highlights safety and tolerability data on lenvatinib/everolimus vs cabozantinib for metastatic ccRCC.

Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today.

Collins stresses the oncological importance of local control, as local recurrences can lead to a "second wave of metastatic disease" that can ultimately cause death.

Suzanne B. Merrill, MD, FACS, discussed the feasibility of integrating immune checkpoint inhibitors into clinical practice for NMIBC, particularly in the community setting.

Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.

Jonathan Henderson, MD, recaps his LUGPA 2025 session, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.”

Safety outcomes were favorable: cystectomy-free survival was 94%, overall survival was 100%, and only 1 patient progressed to muscle-invasive disease.

Marc Machaalani, MD, shares data on soluble MAdCAM-1 as a predictive biomarker in metastatic renal cell carcinoma.

Sisters Amy Pearlman, MD, and Michelle Pearlman, MD, provide an overview of their shared practice, Prime Institute.

Ronney Abaza, MD, predicts the transformative impact that AI will have in robotic surgery.

In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics.

Brooke Edwards, MD, highlights key takeaways from her LUGPA 2025 session, "Transforming your ASC."

Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape.

Martin M. Miner, MD, highlights key findings from TRAVERSE and the T4DM study.

Suzanne Merrill, MD, outlines recent progress with immunotherapy across NMIBC and MIBC.

LUGPA president Scott B. Sellinger, MD, FACS, highlights the key priorities and sessions at this year's LUGPA Annual Meeting.

Data suggest that KIM-1 is prognostic for clinical outcomes in aRCC.

Liu notes that current data—showing a response rate of just over 50%—indicate that the BCG-unresponsive CIS cohort is the most appropriate initial target population.

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy.

Bertrand Tombal, MD, PhD, shares insights from the real-world REASSURE trial.

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025.

Monique Roobol, PhD, MSc, noted that approximately half of the 30% higher incidence of prostate cancer in the screened arm represents overdiagnosis, primarily of low-risk cancers.

Aleece Fosnight, MSPAS, PA-C, encouraged urologists to normalize the conversation by openly acknowledging that these discussions can feel embarrassing but also by celebrating patients for taking the first step.